Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0001652410-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | 2026-01-02 | XERS | Hecht Beth | See Remarks | S - Sale | $7.43 | -16.7K | 1.31M | -1% | -$123.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | S | D | 16,667 | $7.43 | 1,308,103 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.280 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 2,627 shares acquired on June 30, 2025 and 1,967 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended. |